Literature DB >> 20467322

Effects of oxygen inhalation on cardiac output, coronary blood flow and oxygen delivery in healthy individuals, assessed with MRI.

Stefan Bodetoft1, Marcus Carlsson, Håkan Arheden, Ulf Ekelund.   

Abstract

OBJECTIVES: Oxygen (O2) is a cornerstone in the treatment of critically ill patients, and the guidelines prescribe 10-15 l of O2/min even to those who are initially normoxic. Studies using indirect or invasive methods suggest, however, that supplemental O2 may have negative cardiovascular effects. The aim of this study was to test the hypothesis, using noninvasive cardiac magnetic resonance imaging, that inhaled supplemental O2 decreases cardiac output (CO) and coronary blood flow in healthy individuals.
METHODS: Sixteen healthy individuals inhaled O2 at 1, 8 and 15 l/min through a standard reservoir bag mask. A 1.5 T magnetic resonance imaging scanner was used to measure stroke volume, CO and coronary sinus blood flow. Left ventricular (LV) perfusion was calculated as coronary sinus blood flow/LV mass.
RESULTS: The O2 response was dose-dependent. At 15 l of O2/min, blood partial pressure of O2 increased from an average 11.7 to 51.0 kPa with no significant changes in blood partial pressure of CO2 or arterial blood pressure. At the same dose, LV perfusion decreased by 23% (P=0.005) and CO decreased by 10% (P=0.003) owing to a decrease in heart rate (by 9%, P<0.002), with no significant changes in stroke volume or LV dimensions. Owing to the decreased CO and LV perfusion, systemic and coronary O2 delivery fell by 4 and 11% at 8 l of O2/min, despite the increased blood oxygen content.
CONCLUSION: Our data indicate that O2 administration decreases CO, LV perfusion and systemic and coronary O2 delivery in healthy individuals. Further research should address the effects of O2 therapy in normoxic patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20467322     DOI: 10.1097/MEJ.0b013e32833a295e

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  7 in total

1.  Randomized controlled trial of high concentration oxygen in suspected community-acquired pneumonia.

Authors:  Meme Wijesinghe; Kyle Perrin; Bridget Healy; Mark Weatherall; Richard Beasley
Journal:  J R Soc Med       Date:  2012-04-24       Impact factor: 5.344

Review 2.  Supplementary oxygen for nonhypoxemic patients: O2 much of a good thing?

Authors:  Steve Iscoe; Richard Beasley; Joseph A Fisher
Journal:  Crit Care       Date:  2011-06-30       Impact factor: 9.097

3.  Oxygen therapy in patients with ST elevation myocardial infarction based on the culprit vessel: results from the randomized controlled SOCCER trial.

Authors:  Arash Mokhtari; Mahin Akbarzadeh; David Sparv; Pallonji Bhiladvala; Håkan Arheden; David Erlinge; Ardavan Khoshnood
Journal:  BMC Emerg Med       Date:  2020-02-18

4.  Impact of Conservative Versus Conventional Oxygenation on Outcomes of Patients in Intensive Care Units: A Systematic Review and Meta-analysis.

Authors:  Takashi Hirase; Eric S Ruff; Iqbal Ratnani; Salim R Surani
Journal:  Cureus       Date:  2019-09-15

5.  Hyperoxia does not affect oxygen delivery in healthy volunteers while causing a decrease in sublingual perfusion.

Authors:  Bob Smit; Yvo M Smulders; Etto C Eringa; Harry P M M Gelissen; Armand R J Girbes; Harm-Jan S de Grooth; Hans H M Schotman; Peter G Scheffer; Heleen M Oudemans-van Straaten; Angelique M E Spoelstra-de Man
Journal:  Microcirculation       Date:  2018-02       Impact factor: 2.628

6.  High time to omit oxygen therapy in ST elevation myocardial infarction.

Authors:  Ardavan Khoshnood
Journal:  BMC Emerg Med       Date:  2018-10-20

7.  Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se.

Authors:  Anthony Lindholm; Roger Hesselstrand; Göran Rådegran; Håkan Arheden; Ellen Ostenfeld
Journal:  Clin Physiol Funct Imaging       Date:  2019-01-16       Impact factor: 2.273

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.